Klassen Preston 4
4 · Regulus Therapeutics Inc. · Filed Aug 14, 2023
Insider Transaction Report
Form 4
Klassen Preston
DirectorPresident & Head of R & D
Transactions
- Award
Stock Option (Right to Buy)
2023-08-10+225,000→ 225,000 totalExercise: $1.36Exp: 2033-08-09→ Common Stock (225,000 underlying)
Footnotes (1)
- [F1]The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.